ENTA Stock Analysis: Buy, Sell, or Hold?
ENTA - Enanta Pharmaceuticals, Inc
$13.89
-0.17 (-1.21%)
▼
5d:
+15.08%
30d:
-0.43%
90d:
+14.98%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When ENTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ENTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ENTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ENTA is currently trading at $13.89, which is considered extended relative to its 30-day fair value range of $11.64 to $13.62.
Technical Outlook: Technically, ENTA is showing sideways momentum. The price is approaching resistance at $13.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ENTA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.14 (+43.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ENTA is showing sideways momentum. The price is approaching resistance at $13.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ENTA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.14 (+43.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$11.64 -
$13.62
Company Quality Score
58/100
(HOLD)
Options IV Signal
51th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 51th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.3% below Wall St target ($20.14)
Trading Range Analysis
30-Day Trading Range
$11.64 -
$13.62
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.48
(17.8%)
Support & Resistance Levels
Support Level
$10.86
Resistance Level
$13.85
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.19
Wall Street Target
$20.14
(+43.3%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
-66.2%
Profit Margin
-89.6%
Share & Embed Analysis
Last updated: June 24, 2026 2:13 PM ET
Data refreshes hourly during market hours. Next update: 3:13 PM
Data refreshes hourly during market hours. Next update: 3:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced ENTA Option Strategies
Professional options setups generated by AI based on today's ENTA price and gamma walls.
